A New Review of Real-world Experiences of Fluocinolone Acetonide (0.2 μg/day) Intravitreal Implant in the Treatment of Diabetic Macular Oedema
LONDON, October 15, 2015 /PRNewswire/ – European Ophthalmic Review, the peer-reviewed journal, has published a review highlighting the benefits of Real-world Experiences of Fluocinolone Acetonide (0.2 μg/day) Intravitreal Implant in the Treatment of Diabetic Macular Oedema.